NEW YORK--(EON: Enhanced Online News)--The law firm of Wohl & Fruchter LLP is investigating possible violations of federal securities laws by officers and directors of Ariad Pharmaceuticals Inc. (Ariad) (NASDAQ:ARIA).
On October 9, 2013, Ariad announced that its leukemia drug Iclusig causes more blood clots and heart-related side effects than previously reported, forcing the company to halt enrollment in Iclusig clinical trials and advise patients currently on the drug to lower the dose. Simultaneously, the FDA placed a partial clinical hold on all new patient enrollment in clinical trials of Iclusig.
Upon the above news, ARIA shares have declined over 70% in trading on October 9, 2013.
Persons with relevant information, and ARIA shareholders with questions about this investigation, are invited to contact the attorney below, or our Firm by calling 866.833.6245.
Additional information is available on our website at: http://www.wohlfruchter.com/cases/aria.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
This release may be deemed to constitute attorney advertising.